| CTRI Number |
CTRI/2025/06/088705 [Registered on: 12/06/2025] Trial Registered Prospectively |
| Last Modified On: |
11/06/2025 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Nutraceutical |
| Study Design |
Randomized, Crossover Trial |
|
Public Title of Study
|
An Open Label Single Dose Two Period Oral Pharmacokinetic Study In Healthy Adult Human Male And Female Subjects Under Fed Conditions |
|
Scientific Title of Study
|
An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Oral Pharmacokinetic Study Comparing Microactive Pyrroloquinoline Quinone 40mg SR Capsules Manufactured by Kalpatharu Naturals Pvt Ltd U 76 Hootagalli Industrial Area Mysore 570018 Karnataka With Pyrroloquinoline Quinone 40mg IR capsules Manufactured by Kalpatharu Naturals Pvt Ltd U 76 Hootagalli Industrial Area Mysore 570018 Karnataka In Healthy Adult Human Male And Female Subjects Under Fed Conditions |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| SLS-CT-0007-25-PYRR Version: 01 Date: 22 May 25 |
Protocol Number |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Pradeep T |
| Designation |
Principal Investigator |
| Affiliation |
Spinos Lifescience and research private limited |
| Address |
Clinical Pharmacology Unit Ground Floor 29 A Krishna Maduravanam Vellakinarpirivu Thudiyalur Coimbatore
Coimbatore
TAMIL NADU
641029
India
Coimbatore
TAMIL NADU
641029
India |
| Phone |
08220586899 |
| Fax |
|
| Email |
pradeep.t@spinoslifescience.com |
|
Details of Contact Person
Scientific Query
|
| Name |
Dr Pradeep T |
| Designation |
Principal Investigator |
| Affiliation |
Spinos Lifescience and research private limited |
| Address |
Clinical Pharmacology Unit Ground Floor 29 A Krishna Maduravanam Vellakinarpirivu Thudiyalur Coimbatore
Coimbatore
TAMIL NADU
641029
India
TAMIL NADU
641029
India |
| Phone |
08220586899 |
| Fax |
|
| Email |
pradeep.t@spinoslifescience.com |
|
Details of Contact Person
Public Query
|
| Name |
Dr Pradeep T |
| Designation |
Principal Investigator |
| Affiliation |
Spinos Lifescience and research private limited |
| Address |
Clinical Pharmacology Unit Ground Floor 29 A Krishna Maduravanam Vellakinarpirivu Thudiyalur Coimbatore
Coimbatore
TAMIL NADU
641029
India
TAMIL NADU
641029
India |
| Phone |
08220586899 |
| Fax |
|
| Email |
pradeep.t@spinoslifescience.com |
|
|
Source of Monetary or Material Support
|
| Bioactives LLC 1 Dix Street Worcester MA 01609 USA |
|
|
Primary Sponsor
|
| Name |
Bioactives LLC |
| Address |
1 Dix Street Worcester MA 01609 USA |
| Type of Sponsor |
Other [Nutraceutica] |
|
|
Details of Secondary Sponsor
|
| Name |
Address |
| Spinos Life Science andResearch Private limited |
29 A Krishna Madhuravanam Vellakinar Pirivu ThudiyalurCoimbatore 641029 Tamil Nadu India |
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Pradeep T |
Spinos Lifescience andResearch privatelimited |
Clinical Pharmacology unitGround Floor No 29 AKrishna MaduravanamVellakinar pirivu ThudiyalurCoimbatore 641029
Coimbatore
TAMIL NADU
Coimbatore
TAMIL NADU |
08220586899
pradeep.t@spinoslifescience.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Research EthicsCommittee RegistrationNoECR/84/Indt/TN/2013/RR-19 |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Healthy Human Volunteers |
Fed Conditions |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Microactive Pyrroloquinoline Quinone 40mg SR Capsules |
A Single oral dose of Microactive Pyrroloquinoline Quinone 40mg SR Capsules will be administered in each period Total Duration is 09 Days |
| Comparator Agent |
Pyrroloquinoline Quinone 40mg IR capsules |
A Single oral dose of Pyrroloquinoline Quinone 40mg IR capsules will be administered in each period Total Duration is 09 Days |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
45.00 Year(s) |
| Gender |
Both |
| Details |
Normal healthy adult human male and female subjects of age between 18 to 45 years and Body Mass Index ranges between 18 50 kg per m2 to 30 00 kg per m2 according to the formula BMI weight kg per height m2
Subjects who have no evidence of underlying disease during screening and check in and whose screening is performed within 21 days of check in
Subjects whose screening laboratory values are within normal limits are considered by the physician or principal clinical investigator to be of no clinical significance
Healthy as documented by the medical history physical examination including but not limited to an evaluation of the cardiovascular gastrointestinal respiratory musculoskeletal and central nervous system and vital sign assessments
Generally healthy as documented by a 12 lead electrocardiogram ECG Chest X Ray and clinical laboratory assessments
Willing to consume non vegetarian diet and Standard Light breakfast
Willing to comply with all requirements of this study protocol as well as instructions from the study personnel
Non smokers
Generally healthy as documented by gynaecological examination and breast examination period I only
Healthy individuals who were not currently undergoing treatment for any serious disease
Those with a score of 13 or higher in the Activities of Daily Living ADL test questionnaire conducted in advance
Females of childbearing potential must have a negative serum pregnancy test performed within 21 days prior to the initiation of the study and a negative urine pregnancy test prior to check in for each period
If the subject is female currently not pregnant not lactating or not attempting to become pregnant for 4 weeks before the screening visit throughout the duration of the study and 3 weeks after the subject s last study related visit for eligible subjects only if applicable has a negative serum pregnancy test and is of
non childbearing potential defined as
greater or equal to 01 year post menopausal no menstrual period for at least 12consecutive months without any other medical cause
Surgically sterile bilateral tubal ligation bilateral oophorectomy or hysterectomy or is of
childbearing potential willing to commit to using a consistent and acceptablemethod of birth control as defined below for the duration of the study
double barrier methods condoms cervical cap diaphragm and vaginal contraceptivefilm with spermicide
intrauterine device IUD with a low failure rate of less than 1 percentage per year
or is of
childbearing potential and not sexually active willing to commit to using a consistentand acceptable method of birth control as defined above for the duration of thestudy in the event the subject becomes sexually active |
|
| ExclusionCriteria |
| Details |
Evidence of allergy or known hypersensitivity to Pyrroloquinoline Quinone or its inactive ingredients
Subjects with hepatic encephalopathy cholestasis myasthenia pre existing liver disease alcohol abuse existing tinnitus and pre existing gallbladder disease
Any major illness in the last three months or any significant ongoing chronic medical illness
Renal or liver impairment
Any disease or condition that might compromise the haemopoeitic gastrointestinal renal hepatic cardiovascular Musculoskeletal respiratory central nervous system or any other body system including presence of Diabetes Mellitus and Psychosis
History of alcohol addiction or abuse
Consumption of caffeine and /or xanthine containing products ie coffee tea chocolatecaffeine containing sodas colas etc cigarettes and tobacco containing products for atleast 48.00 hours prior to check in and throughout the entire study
Consumption of alcohol and its products grapefruit and or its juice and poppycontaining foods within 48.00 hours prior to clinic admission and throughout theentire study
Subjects who have taken any prescription medications within 14 days prior to studycheck-in and throughout the study and any over the counter medicinal productsherbal medications within 07 days prior to study check in and throughout the study
Subjects who have taken any unusual diet for whatever reason eg low salt for 48.00hours prior to dosing and throughout the study
Subject who had participated in any other study within the 90 days of check in
History of difficulty in swallowing
History of difficulty in accessibility of veins
Positive results for urine screen of drugs of abuse Marijuana THC amphetamine AMPbarbiturates BAR cocaine COC benzodiazepines BZD and morphine MOR in urineprior to check in of each period
Positive results for alcohol test prior to check-in of each period
Any blood donation excess blood loss within 90 days of check-in
Ingestion of any hormonal agent at any time within 14 days prior to the start of thestudy check-in
Use of hormone replacement therapy for a period of 06 months prior to dosing
Female subjects demonstrating a positive pregnancy screen
Female subjects who are currently lactating
Females are likely to become pregnant during the course of the study
|
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Pharmacy-controlled Randomization |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To assess the Pharmacokinetic Study of Comparing Microactive Pyrroloquinoline Quinone 40mg SR Capsules Manufactured by Kalpatharu Naturals Pvt Ltd U 76 Hootagalli Industrial Area Mysore 570018 Karnataka With Pyrroloquinoline Quinone 40mg IR capsules Manufactured by Kalpatharu Naturals Pvt Ltd U 76 Hootagalli Industrial Area Mysore 570018 Karnataka In Healthy Adult Human Male And Female Subjects Under Fed Conditions |
16 time points
00 00 hrs 00 50 hrs 01 00 hrs 01 50 hrs 02 00 hrs 02 25 hrs 02 50 hrs 02 75 hrs 03 00 hrs 03 25 hrs 03 50 hrs 04 00 hrs 06 00 hrs 08 00 hrs 10 00 hrs and 12 00 hrs |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| To monitor the safety and tolerability of test product comparing with the reference product in healthy adult human male and female subjects under fed conditions |
16 time points
00 00 hrs 00 50 hrs 01 00 hrs 01 50 hrs 02 00 hrs 02 25 hrs 02 50 hrs 02 75 hrs 03 00 hrs 03 25 hrs 03 50 hrs 04 00 hrs 06 00 hrs 08 00 hrs 10 00 hrs and 12 00 hrs |
|
|
Target Sample Size
|
Total Sample Size="8"
Sample Size from India="8"
Final Enrollment numbers achieved (Total)= "8"
Final Enrollment numbers achieved (India)="8" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
26/06/2025 |
| Date of Study Completion (India) |
08/09/2025 |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Date Missing |
|
Estimated Duration of Trial
|
Years="0"
Months="6"
Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Completed |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
At least 08 number of healthy
adult human 04 male and 04 female subjects will be recruited to evaluate the
Pharmacokinetic of Test product with the Reference product
As per the discretion of the
Investigator a sufficient number of stand by subjects will be included
additionally to ensure successful dosing of 08 subjects in period I alone
In each period subjects will be
housed in the clinical facility for at least 11 00 hours pre dose to 24 00
hours post dose
A washout period of at least 07
days will be maintained between each dosing period
In each period after an overnight
fasting of at least 08 00 hours prior to Standard Light Breakfast
In the morning Standard Light
Breakfast will be provided 2.00 hours before dosing
After consumption of breakfast
in the morning a single oral dose of either the test product T or reference
product R will be administered as per the randomization schedule with 240 mL of
drinking water at ambient temperature
Blood pressure
radial pulse rate body temperature and
wellbeing status will be enquired and recorded at and 00 00 hour within 75
minutes of before dosing and at 01 00 03 00 06 00 and 11 00 hours plus or minus
60 minutes post dose
Monitoring for
adverse events will be done throughout the study period in clinical phase |